ARCHIVES

FDA Advisors Debate Ban, Black Box And Status Quo of Power Morcellators

This article is from The Cancer Letter archive.

Vol. 40 No. 30 | July 25, 2014

Download PDF Visit The Full Archive

Related Articles

Chemoprevention Clinical Trial RFA Being Developed For January Concept Review, Along With “Bridge” RFA

November 27, 1981

ACCC Committee Hears Alternative Ways To Do Clinical Trials In Community

May 8, 1981

Study Of Tamoxifen And Raloxifene Enrolls 6,000 In First Year; 5 Percent Are Minorities

July 28, 2000

DCPC Board Okays Core Grant Changes On Shared Resources

January 30, 1987

Why Four? NCI Official Challenged To Explain Rational For Proposed Number Of Groups

March 25, 2011

FDA Needs Staff, Funds But first Must Determine Priorities, GAO Says

November 17, 1989